To study the effects of a powder in men and women who have fungal infection.

Evaluation of the effectiveness and tolerability of Candid Dusting powder in participants with dermatophytosis. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/05/110441

Enrollment

Registered

2026-05-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Candid Dusting Powder: The affected area will be cleaned and dried. The dusting powder will be applied on the affected area and some on the surrounding skin and spread as instructed, tw

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals who are willing to understand and sign a written informed consent form prior to the study. 2. Male and female individuals aged between 18 to 65 years (both values included). 3. Clinically Diagnosed patients with mild to moderate cutaneous dermatophytosis with itching and H/O excessive sweating. 4. Willingness to participate in the study and comply with the study procedures and required visits.

Exclusion criteria

Exclusion criteria: 1. Patients with extensive dermatophytosis, superadded bacterial infection. 2. Patients with dermatitis such as contact dermatitis, atopic dermatitis, psoriasis, other skin diseases 3. Pregnant women as confirmed by UPT and lactating women. 4. Participants with any significant medical illness such as diabetes, immunocompromised conditions, and other sexually transmitted diseases, etc. 5. Participants with a history of hypersensitivity to azole antifungals 6. Participants who received topical antifungal within 1 week before baseline visit and participants who received systemic antifungals within 4 weeks. 7. Topical steroid based formulation usage 8. Oral antihistamine usage.

Design outcomes

Primary

Measure	Time frame
1) Mean time (in hours ) to achieve noticeable improvement in itch as reported by participant from baseline in VAS pruritus score 2) Percentage of patients showing itch improvement at different time intervals 3) Mean time period of sweat absorption (no sweating) as reported by patients 4) Percentage of patients showing sweat absorption (no sweating) at different time intervalsTimepoint: Baseline, 30 mins, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours	—

Measure

Time frame

1) Mean time (in hours ) to achieve noticeable improvement in itch as reported by participant from baseline in VAS pruritus score 2) Percentage of patients showing itch improvement at different time intervals 3) Mean time period of sweat absorption (no sweating) as reported by patients 4) Percentage of patients showing sweat absorption (no sweating) at different time intervalsTimepoint: Baseline, 30 mins, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours

—

Secondary

Measure	Time frame
Number of participants with any serious and non-serious adverse events.Timepoint: Baseline, 30 mins, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours	—

Countries

India

Contacts

Public ContactMs Preetha Paul

Clinical Aesthetics and Investigative Management Service Pvt. Ltd. (C.L.A.I.M.S.PVT.LTD.

preetha@claimsclinical.com66758851

Outcome results